WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc (ALNY) announced its key 'Alnylam 5x15' and partner program goals for 2012.
Alnylam said it aims to accelerate advancement of its ALN-TTR program, which targets the transthyretin or TTR gene for the treatment of transthyretin-mediated amyloidosis or ATTR and Alnylam expects ALN-TTR02 to be the 'go-to-market' drug candidate for the company's ATTR program; ALN-TTR02 is comprised of an siRNA formulated in a proprietary second generation lipid nanoparticle.
The company stated that the primary objective of the study is to evaluate the safety and tolerability of a single dose of ALN-TTR02, with subjects being enrolled into five sequential dose cohorts ranging from 0.01 to 0.50 mg/kg. Alnylam plans to begin enrollment of this clinical trial in the first half of 2012 and expects to report data in the third quarter of 2012.
In addition, Alnylam recently completed patient enrollment in its Phase IIb study with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus or RSV infection, and expects to report results in mid-2012. The Phase IIb trial was designed as a multi-center, randomized, double-blind, placebo-controlled study in RSV-infected lung transplant patients.
Further, the company added that it expects to form additional partnerships in 2012 related to its 'Alnylam 5x15' and partner-based programs. Further, the company aims to form additional partnerships related to non-therapeutic applications of RNAi technology including Alnylam Biotherapeutics and its VaxiRNATM platform.
Copyright RTT News/dpa-AFX